Acute canagliflozin treatment protects against in vivo myocardial ischemia–reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation
The sodium–glucose cotransporter-2 (SGLT2) inhibitor canagliflozin has been shown to reduce major cardiovascular events in type 2 diabetic patients, with a pronounced decrease in hospitalization for heart failure (HF) especially in those with HF at baseline. These might indicate a potent direct card...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
16 April 2019
|
| In: |
Journal of translational medicine
Year: 2019, Volume: 17, Pages: 1-14 |
| ISSN: | 1479-5876 |
| DOI: | 10.1186/s12967-019-1881-8 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1186/s12967-019-1881-8
|
| Author Notes: | Alex Ali Sayour, Sevil Korkmaz-Icöz, Sivakkanan Loganathan, Mihály Ruppert, Viktor Nabil Sayour, Attila Oláh, Kálmán Benke, Maik Brune, Rita Benkő, Eszter Mária Horváth, Matthias Karck, Béla Merkely, Tamás Radovits and Gábor Szabó |
Search Result 1
Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation
BioMed Central 18 Jun. 2019 Universitätsbibliothek Heidelberg 18 Jun. 2019
Article (Journal)
Book/Monograph
Online Resource